{"id":22869,"date":"2026-09-02T14:13:17","date_gmt":"2026-09-02T12:13:17","guid":{"rendered":"https:\/\/mic-site.labiux.com\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/"},"modified":"2026-09-02T14:13:17","modified_gmt":"2026-09-02T12:13:17","slug":"vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/","title":{"rendered":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu. \u0160oned\u0113\u013c risin\u0101jums tika mekl\u0113ts diskusij\u0101 \u201cVai r\u012bt mums v\u0113l b\u016bs z\u0101les? Kr\u012bze Latvijas medic\u012bn\u0101\u201d, piedaloties Latvijas Patentbr\u012bvo medikamentu asoci\u0101cijas (LPMA) valdes priek\u0161s\u0113d\u0113t\u0101jam <strong>Egilam Ein\u0101ram Jur\u0161evicam<\/strong>, Vesel\u012bbas ministrijas Farm\u0101cijas departamenta direktorei <strong>Inesei Kauperei<\/strong>, Latvijas Lauku \u0123imenes \u0101rstu asoci\u0101cijas prezidentam <strong>Ainim Dzalbam<\/strong> un Latvijas Vesel\u012bbas ekonomikas asoci\u0101cijas valdes loceklim <strong>Uldim H\u013cevickim<\/strong>. Visi diskusijas dal\u012bbnieki atzina, ka \u0161\u012b br\u012b\u017ea sist\u0113ma nav ilgtsp\u0113j\u012bga un nepiecie\u0161ams mekl\u0113t risin\u0101jumus.<\/p>\n<p><strong>Mazam tirgum j\u0101sp\u0113j konkur\u0113t par ra\u017eot\u0101ju uzman\u012bbu<\/strong><\/p>\n<p>P\u0113t\u012bjumi liecina, ka Latvij\u0101 pacientiem piec\u0101s visizplat\u012bt\u0101kaj\u0101s medikamentu grup\u0101s ir pieejams maz\u0101ks z\u0101\u013cu nek\u0101 citur Eirop\u0101. Pat maz\u0101k nek\u0101 m\u016bsu kaimi\u0146valst\u012bs. Runa ir ne tikai par inovat\u012bvajiem medikamentiem, bet ar\u012b patentbr\u012bvajiem medikamentiem. Tie 2025. gad\u0101 veidoja 76% no visiem Latvijas iedz\u012bvot\u0101ju lietotajiem medikamentiem, vienlaikus pat\u0113r\u0113jot tikai 43% no kompens\u0113jamo z\u0101\u013cu bud\u017eeta.<\/p>\n<p>Pieejam\u012bbas tr\u016bkumu veicina vair\u0101ki faktori. P\u0113d\u0113jo gadu laik\u0101 infl\u0101cija Eirop\u0101 k\u0101pusi vair\u0101kk\u0101rt. Elektroener\u0123ijas cenas ir pieaugu\u0161as par 40%, savuk\u0101rt g\u0101zes cenas ir dubultoju\u0161\u0101s. Ku\u0123u kravu p\u0101rvad\u0101jumi k\u013cuvu\u0161i se\u0161as reizes d\u0101rg\u0101ki, bet gaisa kravu izmaksas augu\u0161as par vair\u0101k nek\u0101 30%. Medikamentu iepirk\u0161anas cena netiek celta atbilsto\u0161i ra\u017eo\u0161anas izmaksu k\u0101pumam un \u0161obr\u012bd ra\u017eot\u0101ji nereti nesp\u0113j nosegt medikamentu izgatavo\u0161anas izmaksas.\u00a0 T\u0101d\u0113\u013c 46% no kritiski svar\u012bgajiem patentbr\u012bvajiem medikamentiem, kurus lieto visa Eiropa, ra\u017eo tikai viens ra\u017eot\u0101js. \u0160\u012b ir ne tikai Latvijas, bet Eiropas probl\u0113ma, jo jebk\u0101di trauc\u0113jumi ra\u017eo\u0161an\u0101 vai pieg\u0101des \u0137\u0113d\u0113 var b\u016btiski ietekm\u0113t z\u0101\u013cu pieejam\u012bbu. Tom\u0113r at\u0161\u0137ir\u012bb\u0101 no cit\u0101m ES valst\u012bm, m\u016bsu tirgus ir \u013coti mazs, bet birokr\u0101tiskais slogs augsts. Attiec\u012bgi ra\u017eot\u0101ji priorit\u0101ri izv\u0113las medikamentus realiz\u0113t cit\u0101s valst\u012bs, pametot Latvijas tirgu.<\/p>\n<p>\u201cMedikamentu ra\u017eot\u0101jiem, t\u0101pat k\u0101 maizes vai piena ra\u017eot\u0101jiem, j\u0101dom\u0101 par to, k\u0101 segt produktu pa\u0161izmaksu. Tom\u0113r piena un maizes cenas aug nep\u0101rtraukti, kam\u0113r kompens\u0113jamo medikamentu iepirk\u0161an\u0101s cenas liel\u0101 da\u013c\u0101 gad\u012bjumu nepaaugstin\u0101s. Ministru kabineta noteikumi pieprasa, ka medikamentu cen\u0101m j\u0101b\u016bt l\u012bdzv\u0113rt\u012bg\u0101m vis\u0101s Baltijas kaimi\u0146valst\u012bs. Tikm\u0113r ra\u017eot\u0101jam Latvij\u0101 par medikamentu uztur\u0113\u0161anu Latvijas tirg\u016b ir j\u0101maks\u0101 administrat\u012bv\u0101s izmaksas, kas nav ne Lietuv\u0101, ne Igaunij\u0101. Atkar\u012bb\u0101 no tirg\u016b eso\u0161\u0101 medikamentu skaita, vienam ra\u017eot\u0101jam \u0161\u012bs izmaksas var sasniegt pat desmitiem t\u016bksto\u0161us gad\u0101. Da\u017eas nodevas j\u0101maks\u0101 pat tad, ja realit\u0101t\u0113 gada laik\u0101 netiek p\u0101rdots neviens medikamenta iepakojums. Nodevas ir vien\u0101di augstas gan inovat\u012bvajiem medikamentiem, kuru iepakojums maks\u0101, piem\u0113ram, 10\u00a0000 EUR, gan kardiolo\u0123ij\u0101 izmantotajam patentbr\u012bvajam medikamentam, kuru ra\u017eot\u0101ja cena kompens\u0113jamo z\u0101\u013cu sarakst\u0101 ir 22 centi. \u0145emot v\u0113r\u0101 mazo tirgu un apgroz\u012bjumu, k\u0101 ar\u012b jau t\u0101 zem\u0101s medikamentu iepirk\u0161anas cenas, \u0161\u0101das izmaksas ir b\u016btisks papildu slogs,\u201d pau\u017e Jur\u0161evics.<\/p>\n<p>Sarun\u0101 Jur\u0161evics izteica pateic\u012bbu atbild\u012bgaj\u0101m instanc\u0113m par p\u0113d\u0113jos gados realiz\u0113taj\u0101m sarun\u0101m un veiktaj\u0101m darb\u012bb\u0101m situ\u0101cijas uzlabo\u0161anai, taj\u0101 skait\u0101 Z\u0101\u013cu valsts a\u0123ent\u016bras uzturmaksas nodevu samazinot par aptuveni 11%. Tom\u0113r tas nesp\u0113j atrisin\u0101t samilzu\u0161o probl\u0113mu un vair\u0101ki ra\u017eot\u0101ji \u0161obr\u012bd run\u0101 par to, ka ja situ\u0101cija strauji nemain\u012bsies, vi\u0146iem n\u0101ksies pamest Latvijas tirgu. No 2022. l\u012bdz 2025. gadam no kompens\u0113jamo z\u0101\u013cu sarakst\u0101 sv\u012btroti 553 medikamenti, no kuriem liel\u0101k\u0101 da\u013ca ir patentbr\u012bvie medikamenti.<\/p>\n<p><strong>Maz\u0101k ra\u017eot\u0101ju noz\u012bm\u0113 maz\u0101ku izv\u0113li \u0101rstiem un pacientiem<\/strong><\/p>\n<p>Latvijas Lauku \u0123imenes \u0101rstu asoci\u0101cijas prezidents Ainis Dzalbs uzsver, ka situ\u0101cija nav v\u0113rt\u0113jama viennoz\u012bm\u012bgi. P\u0113d\u0113jos gados sadarb\u012bb\u0101 ar Vesel\u012bbas ministriju z\u0101\u013cu pieejam\u012bb\u0101 ir pan\u0101kts b\u016btisks progress, piem\u0113ram, papla\u0161in\u0101ta diab\u0113ta un kardiolo\u0123ij\u0101 pielietoto medikamentu pieejam\u012bba. Att\u012bst\u012bba un pozit\u012bva virz\u012bba viennoz\u012bm\u012bgi notiek. Tom\u0113r vienlaikus arvien bie\u017e\u0101k \u0101rstiem n\u0101kas saskarties ar ierobe\u017eotu medikamentu izv\u0113li, \u012bpa\u0161i hronisku slim\u012bbu \u0101rst\u0113\u0161an\u0101.<\/p>\n<p>\u201cNav t\u0101, ka viss ir slikti, bet ar\u012b nevaram teikt, ka situ\u0101cija ir laba. M\u0113s redzam uzlabojumus, ta\u010du pieejam\u012bbas jaut\u0101jum\u0101 ir j\u0101dara v\u0113l vair\u0101k. Pand\u0113mijas laik\u0101 s\u0101k\u0101m \u013coti skaidri redz\u0113t pieg\u0101des \u0137\u0113\u017eu un lo\u0123istikas probl\u0113mas, ta\u010du, p\u0113tot \u0161o jaut\u0101jumu padzi\u013cin\u0101t\u0101k, saprat\u0101m, ka medikamentu pieejam\u012bbu ietekm\u0113 ar\u012b birokr\u0101tiskie un administrat\u012bvie \u0161\u0137\u0113r\u0161\u013ci, kas kav\u0113 gan ori\u0123in\u0101lo, gan patentbr\u012bvo medikamentu ien\u0101k\u0161anu m\u016bsu mazaj\u0101 tirg\u016b,\u201d nor\u0101da Dzalbs.<\/p>\n<p>Vi\u0146\u0161 skaidro, ka probl\u0113ma nav tikai teor\u0113tiska. \u0122imenes \u0101rstu praks\u0113s jau ir biju\u0161as situ\u0101cijas, kad nav pieejama konkr\u0113ta pacientam nepiecie\u0161am\u0101 akt\u012bv\u0101 viela. \u012apa\u0161i b\u016btiski tas ir hronisku slim\u012bbu \u0101rst\u0113\u0161an\u0101, piem\u0113ram, kardiolo\u0123ij\u0101 un endokrinolo\u0123ij\u0101, kur atsevi\u0161\u0137iem medikamentiem ne vienm\u0113r ir pieejama l\u012bdzv\u0113rt\u012bga alternat\u012bva. \u201cRa\u017eot\u0101ju k\u013c\u016bst arvien maz\u0101k, un lab\u0101kaj\u0101 gad\u012bjum\u0101 \u0123imenes \u0101rstam ir iesp\u0113ja izv\u0113l\u0113ties starp viena vai divu ra\u017eot\u0101ju medikamentiem. Tas noz\u012bm\u0113, ka pacientam ne vienm\u0113r var\u0113sim pied\u0101v\u0101t l\u0113t\u0101ko pieejamo alternat\u012bvu. Ta\u010du v\u0113l b\u016btisk\u0101k \u2013 var pien\u0101kt situ\u0101cija, kad konkr\u0113tai \u0101rst\u0113\u0161anai nepiecie\u0161am\u0101s z\u0101les Latvij\u0101 vienk\u0101r\u0161i neb\u016bs pieejamas,\u201d uzsver Latvijas Lauku \u0123imenes \u0101rstu asoci\u0101cijas prezidents.<\/p>\n<p>Tikm\u0113r Latvijas Vesel\u012bbas ekonomikas asoci\u0101cijas valdes loceklis Uldis H\u013cevickis skaidroja, ka dom\u0101jot par vesel\u012bbas ekonomikas uzlabo\u0161anu, svar\u012bgi dom\u0101t par balansu: \u201cRun\u0101jot par vesel\u012bbas ekonomiku, vispirms ir j\u0101run\u0101 par ekonomikas pamatprincipiem. Un viens no tiem ir vesel\u012bgas konkurences veido\u0161ana un da\u017e\u0101du instrumentu un meh\u0101nismu ievie\u0161ana, kas \u0161o konkurenci veicin\u0101tu. P\u0113d\u0113jos gados vair\u0101k esam piesk\u0101ru\u0161ies inovat\u012bvajiem medikamentiem, kas ir \u013coti labi un \u013coti svar\u012bgi, jo m\u0113s saprotam, ka tehnolo\u0123ijas un diagnostikas metodes att\u012bst\u0101s. Ta\u010du mums j\u0101atrod balanss starp inovat\u012bvo medikamentu finans\u0113\u0161anu un to medikamentu finans\u0113\u0161anu, kas pal\u012bdz liel\u0101kajai popul\u0101cijas da\u013cai.\u201d<\/p>\n<p><strong>Nepiecie\u0161ami jauni risin\u0101jumi z\u0101\u013cu pieejam\u012bbas stiprin\u0101\u0161anai<\/strong><\/p>\n<p>Diskusij\u0101 Vesel\u012bbas ministrijas Farm\u0101cijas departamenta direktore Inese Kaupere uzsv\u0113ra, ka pand\u0113mija, p\u0113d\u0113jo gadu infl\u0101cija un ar to saist\u012btais izmaksu pieaugums ir rad\u012bjis jaunus izaicin\u0101jumus z\u0101\u013cu pieejam\u012bbai. T\u0101d\u0113\u013c nepiecie\u0161ams mekl\u0113t jaunus risin\u0101jumus, vienlaikus nor\u0101dot uz pozit\u012bv\u0101m izmai\u0146\u0101m z\u0101\u013cu pieejam\u012bbas jom\u0101.<\/p>\n<p>\u201cP\u0113d\u0113jo gadu laik\u0101 ir notiku\u0161as vair\u0101kas pozit\u012bvas izmai\u0146as \u2013 statistika par\u0101da, ka pacientiem medikamenti ir k\u013cuvu\u0161i pieejam\u0101ki, ar\u012b l\u012bdzek\u013ci, kas t\u0113r\u0113ti medikamentos samazin\u0101s. Par\u0101d\u0101s arvien jaunas terapijas iesp\u0113jas un medikamenti ne tikai iet prom, bet ar\u012b ien\u0101k m\u016bsu tirg\u016b. Protams, ir v\u0113l daudzas lietas, kas j\u0101uzlabo. J\u0101\u0146em v\u0113r\u0101, ka vajadz\u012bbas ir \u013coti lielas. M\u0113s kompens\u0113jamiem medikamentiem pie\u0161\u0137irtaj\u0101 finans\u0113jum\u0101 \u013coti tiecamies sasniegt Baltijas valstu l\u012bmeni. Katru gadu tiek pie\u0161\u0137irts papildus finans\u0113jums, bet tas nav pietiekams, lai m\u0113s paveiktu visu. M\u0113s akt\u012bvi dom\u0101jam par to, k\u0101 papla\u0161in\u0101t jaunu medikamentu kl\u0101stu un k\u0101 varam uzlabot medikamentu pieejam\u012bbu. M\u0113s saprotam, ka vien\u0101 br\u012bd\u012b rodas situ\u0101cija, kad z\u0101\u013cu cenas j\u0101pace\u013c, lai ir pieejama medikamentu da\u017e\u0101d\u012bba. Bet te atkal atduramies pieejamaj\u0101 finans\u0113jum\u0101. Probl\u0113ma ir daudz dzi\u013c\u0101ka, ne tikai uzturmaks\u0101, kas j\u0101sedz ra\u017eot\u0101jam. Vesel\u012bbas ministrija ir atv\u0113rta pla\u0161\u0101kai diskusijai ar nozari, lai kop\u012bgi mekl\u0113tu risin\u0101jumus,\u201d nor\u0101da Kaupere.<\/p>\n<p>Asoci\u0101cija turpin\u0101s sarunas ar politiskajiem sp\u0113kiem, Vesel\u012bbas ministriju un cit\u0101m iesaist\u012btaj\u0101m pus\u0113m, lai pan\u0101ktu risin\u0101jumus, kas ilgtermi\u0146\u0101 stiprin\u0101tu z\u0101\u013cu pieejam\u012bbu Latvij\u0101. LPMA ieskat\u0101 nepiecie\u0161ams palielin\u0101t kompens\u0113jamiem medikamentiem un vesel\u012bbas apr\u016bpei atv\u0113l\u0113to bud\u017eetu, mazin\u0101t administrat\u012bvo slogu ra\u017eot\u0101jiem, veicin\u0101t konkurenci un nodro\u0161in\u0101t stabilu kritisko un ikdien\u0101 nepiecie\u0161amo patentbr\u012bvo medikamentu pieejam\u012bbu. M\u0113r\u0137im j\u0101b\u016bt vienam \u2013 lai Latvijas pacientiem b\u016btu pieejamas gan inovat\u012bv\u0101s z\u0101les, gan pla\u0161i lietotie patentbr\u012bvie medikamenti.<\/p>\n<p>Avots: LETA<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":13853,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[76,73],"tags":[414],"mic_flag":[],"class_list":["post-22869","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunakie-raksti","category-medikamentu-zinas","tag-zalu-pieejamiba"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-09-02T12:13:17+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-09-02T12:13:17+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"name\":\"Medikamenti\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"position\":2,\"name\":\"Medikamenti\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#listItem\",\"name\":\"Vai Latvij\\u0101 n\\u0101kotn\\u0113 pietiks ikdien\\u0101 nepiecie\\u0161amo z\\u0101\\u013cu? Eksperti diskut\\u0113 par pieaugo\\u0161iem pieejam\\u012bbas riskiem\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#listItem\",\"position\":3,\"name\":\"Vai Latvij\\u0101 n\\u0101kotn\\u0113 pietiks ikdien\\u0101 nepiecie\\u0161amo z\\u0101\\u013cu? Eksperti diskut\\u0113 par pieaugo\\u0161iem pieejam\\u012bbas riskiem\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"name\":\"Medikamenti\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#newsarticle\",\"name\":\"Vai Latvij\\u0101 n\\u0101kotn\\u0113 pietiks ikdien\\u0101 nepiecie\\u0161amo z\\u0101\\u013cu? Eksperti diskut\\u0113 par pieaugo\\u0161iem pieejam\\u012bbas riskiem - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"Vai Latvij\\u0101 n\\u0101kotn\\u0113 pietiks ikdien\\u0101 nepiecie\\u0161amo z\\u0101\\u013cu? Eksperti diskut\\u0113 par pieaugo\\u0161iem pieejam\\u012bbas riskiem\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg\",\"width\":2048,\"height\":1365},\"datePublished\":\"2026-09-02T14:13:17+03:00\",\"dateModified\":\"2026-09-02T14:13:17+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#webpage\"},\"articleSection\":\"Jaun\\u0101kie raksti, Medikamenti, Z\\u0101\\u013cu pieejam\\u012bba\",\"dateline\":\"Published on September 2, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/\",\"name\":\"Vai Latvij\\u0101 n\\u0101kotn\\u0113 pietiks ikdien\\u0101 nepiecie\\u0161amo z\\u0101\\u013cu? Eksperti diskut\\u0113 par pieaugo\\u0161iem pieejam\\u012bbas riskiem - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Kad run\\u0101jam par z\\u0101\\u013cu pieejam\\u012bbu, sabiedr\\u012bbas uzman\\u012bba visbie\\u017e\\u0101k tiek piev\\u0113rsta jauniem un d\\u0101rgiem inovat\\u012bviem medikamentiem. Lai ar\\u012b par to run\\u0101t ir \\u013coti noz\\u012bm\\u012bgi, ne maz\\u0101k b\\u016btisks ir jaut\\u0101jums \\u2013 vai Latvij\\u0101 ar\\u012b turpm\\u0101k b\\u016bs z\\u0101les, kuras cilv\\u0113ki lieto ikdien\\u0101? Ra\\u017eot\\u0101ji ce\\u013c trauksmi, jo pa\\u0161reiz\\u0113j\\u0101 z\\u0101\\u013cu cenu un kompens\\u0101cijas sist\\u0113ma ilgtermi\\u0146\\u0101 apdraud ikdien\\u0101 nepiecie\\u0161amo medikamentu pieejam\\u012bbu.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#mainImage\",\"width\":2048,\"height\":1365},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\\\/#mainImage\"},\"datePublished\":\"2026-09-02T14:13:17+03:00\",\"dateModified\":\"2026-09-02T14:13:17+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs","description":"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.","canonical_url":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","name":"Medikamenti"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","position":2,"name":"Medikamenti","item":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#listItem","name":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#listItem","position":3,"name":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","name":"Medikamenti"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#newsarticle","name":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs","headline":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg","width":2048,"height":1365},"datePublished":"2026-09-02T14:13:17+03:00","dateModified":"2026-09-02T14:13:17+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#webpage"},"articleSection":"Jaun\u0101kie raksti, Medikamenti, Z\u0101\u013cu pieejam\u012bba","dateline":"Published on September 2, 2026."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/","name":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs","description":"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg","@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#mainImage","width":2048,"height":1365},"primaryImageOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/#mainImage"},"datePublished":"2026-09-02T14:13:17+03:00","dateModified":"2026-09-02T14:13:17+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs","og:description":"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.","og:url":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/","og:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg","og:image:secure_url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg","og:image:width":2048,"og:image:height":1365,"article:published_time":"2026-09-02T12:13:17+00:00","article:modified_time":"2026-09-02T12:13:17+00:00","twitter:card":"summary_large_image","twitter:title":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Kad run\u0101jam par z\u0101\u013cu pieejam\u012bbu, sabiedr\u012bbas uzman\u012bba visbie\u017e\u0101k tiek piev\u0113rsta jauniem un d\u0101rgiem inovat\u012bviem medikamentiem. Lai ar\u012b par to run\u0101t ir \u013coti noz\u012bm\u012bgi, ne maz\u0101k b\u016btisks ir jaut\u0101jums \u2013 vai Latvij\u0101 ar\u012b turpm\u0101k b\u016bs z\u0101les, kuras cilv\u0113ki lieto ikdien\u0101? Ra\u017eot\u0101ji ce\u013c trauksmi, jo pa\u0161reiz\u0113j\u0101 z\u0101\u013cu cenu un kompens\u0101cijas sist\u0113ma ilgtermi\u0146\u0101 apdraud ikdien\u0101 nepiecie\u0161amo medikamentu pieejam\u012bbu.","twitter:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2024\/04\/Know-Counterfeit-Drugs-viltotas-zales-verifikacija.jpg"},"aioseo_meta_data":{"post_id":"22869","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-16 20:15:02","updated":"2026-10-16 20:15:02"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/\" title=\"Medikamenti\">Medikamenti<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tVai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Medikamenti","link":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/"},{"label":"Vai Latvij\u0101 n\u0101kotn\u0113 pietiks ikdien\u0101 nepiecie\u0161amo z\u0101\u013cu? Eksperti diskut\u0113 par pieaugo\u0161iem pieejam\u012bbas riskiem","link":"https:\/\/farmacija-mic.lv\/en\/vai-latvija-nakotne-pietiks-ikdiena-nepieciesamo-zalu-eksperti-diskute-par-pieaugosiem-pieejamibas-riskiem\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=22869"}],"version-history":[{"count":0,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22869\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media\/13853"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=22869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=22869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=22869"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=22869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}